Fulvestrant-Mediated Attenuation of the Innate Immune Response Decreases ER+ Breast Cancer Growth <i>In Vivo</i> More Effectively than Tamoxifen

Annelie Abrahamsson(Industrial Development Center (Sweden)), Charlotta Dabrosin(Linköping University)
Cancer Research
August 27, 2020
10.1158/0008-5472.can-20-1705
Cited by 21

Related Papers

Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ
|Oncotarget|2016|48